Brokerages Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has earned a consensus rating of “Buy” from the five research firms that are covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $12.38.

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Corvus Pharmaceuticals in a research report on Tuesday, January 14th.

Institutional Trading of Corvus Pharmaceuticals

Large investors have recently bought and sold shares of the business. Virtus ETF Advisers LLC bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth approximately $47,000. Nwam LLC bought a new stake in Corvus Pharmaceuticals during the 3rd quarter worth approximately $53,000. PKS Advisory Services LLC bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth approximately $56,000. Alpine Global Management LLC bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth approximately $62,000. Finally, ExodusPoint Capital Management LP bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth approximately $72,000. 46.64% of the stock is owned by institutional investors.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ:CRVS opened at $4.21 on Tuesday. The company has a market capitalization of $270.52 million, a price-to-earnings ratio of -4.53 and a beta of 0.91. The firm’s 50 day simple moving average is $4.76 and its 200 day simple moving average is $6.07. Corvus Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $10.00.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.